Compare CAVA Group Inc (CAVA) vs Gilead Sciences, Inc. (GILD) Price & Performance

CAVA trades at $69.68, up 13.15% with strong Q2 2026 earnings beats and 31.3% revenue growth. Technicals are bearish with support at $58, while fundamentals show high P/E of 108.59 but robust same-store sales. News highlights include menu innovation driving traffic and earnings outperformance.

Outlook is positive with a $89.75 consensus price target and 76% buy ratings, though valuation and net cash outflows pose risks. Growth momentum from new restaurants and consumer demand supports upside, but margin pressure and competition require monitoring.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.